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Summary
 
Graves’ Disease results from the production of autoantibodies against receptors for thyroid
stimulating hormone (TSH) on thyroid epithelial cells, and represents the prototype for nu-
merous autoimmune diseases caused by autoantibodies that bind to organ-specific cell mem-
brane antigens. To study how humoral tolerance is normally maintained to organ-specific
membrane antigens, transgenic mice were generated selectively expressing membrane-bound
hen egg lysozyme (mHEL) on the thyroid epithelium. In contrast to the deletion of autoreactive B
cells triggered by systemic mHEL (Hartley, S.B., J. Crosbie, R. Brink, A.B. Kantor, A. Basten,
and C.C. Goodnow. 1991. 
 
Nature.
 
 353:765–769), selective expression of mHEL autoantigen
on thyroid cells did not trigger elimination or inactivation of circulating HEL-reactive B cells.
These results provide evidence that tolerance is not actively acquired to organ-specific antigens
in the preimmune B cell repertoire, underscoring the importance of maintaining tolerance to
such antigens by other mechanisms. The role of an intact endothelial barrier in sequestering or-
gan-specific antigens from circulating preimmune B cells is discussed.
 
A
 
utoantibodies directed against molecules that are
unique to the surface of cells in the parenchyma of dis-
crete organs underlie the pathogenesis of a variety of or-
gan-specific autoimmune diseases (1). For example, pro-
duction of autoantibodies that bind to and stimulate the
thyroid-stimulating hormone (TSH) receptor cause the
thyrotoxicosis of Graves’ Disease, and anti-thyroid peroxi-
dase antibody in Graves’ and Hashimoto’s thyroiditis is
thought to inhibit thyroid function and promote comple-
ment deposition and thyroid destruction (2). Similarly, an-
tibodies to the acetylcholine receptor interfere with neuro-
muscular synaptic transmission in Myasthenia Gravis (3),
antibodies to epithelial cell cadherins cause cell detachment
in bullous pemphigoid and pemphigus vulgaris (4), and an-
tibodies against type IV collagen lead to Goodpasture’s Dis-
ease (5).
Recent studies have established that one bulwark block-
ing the production of autoantibodies against self antigens
that are displayed in the bloodstream or on the surface of
circulating cells is the active elimination or inactivation of
self-reactive B cells from the preimmune repertoire (6–10).
This process operates for autoantibodies even with very
low affinity to membrane-bound self-antigen (11, 12). By
contrast, for organ-specific antigens, the relative ease with
which autoimmunity can be induced by immunization has
long suggested that B cell inactivation or elimination is ei-
ther reversed by immunization with potent adjuvants (13,
 
14) or that the B cell repertoire is simply not censored to
these types of antigens. Ig gene transgenic mice have been
used to test these alternatives for one organ-specific antigen
in mice expressing a K
 
b
 
 histocompatibility antigen on
hepatocytes (MT-K
 
b
 
) (15). In this case, the K
 
b
 
-specific B
cells were clonally deleted from the preimmune repertoire.
The K
 
b
 
 antigen in these mice was controlled by the metal-
lothionein promoter, however, which is active in many tis-
sues, including bone marrow–derived cells (16), so that B
cell deletion to MT-K
 
b
 
 may have reflected low-level sys-
temic antigen expression.
To determine whether autoreactive B cells are normally
eliminated or inactivated to self-antigen displayed selec-
tively on the surface of parenchymal cells in specific organs,
we have modified a systemically expressed membrane hen
egg lysozyme (HEL)
 
1
 
 transgene (9) to direct expression ex-
clusively to the thyroid epithelium. The thyroid gland was
chosen as a prototype for several reasons. First, the thyroid
is a highly vascularized tissue, so that antigens expressed
uniquely in the thyroid should not be physically seques-
tered from the circulating immune system (17), as may oc-
 
1
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cur in the eye or brain. Second, the thyroid epithelium has
considerable regenerative potential and is physically well
characterized. Third, animal models of experimental au-
toimmune thyroiditis (EAT) have suggested that humoral
tolerance to thyroid-specific antigens is easily broken or
nonexistent (18, 14). Tolerance to thyroid antigens also
seems fragile in humans, as 
 
.
 
40% of women 20 yr or over
show thyroid inflammation at autopsy (19). Finally, au-
toantibodies directed against thyroid-specific antigens have
a well-established role in the pathogenesis of autoimmune
thyroid disease (2). By using Ig transgenic mice that have
previously shown elimination (9) or inactivation (6) of B
cells to systemic antigens, we find that, by contrast, thy-
roid-specific membrane-bound HEL (mHEL) induces no
detectable censoring of the preimmune B cell repertoire.
 
Materials and Methods
 
Creation of TLK Transgenic Mouse Lines.
 
The TLK gene con-
struct uses the rat thyroglobulin (rTg) promoter to direct expres-
sion of mHEL on the thyroid epithelium. The rTg promoter was
excised from pTg-neo (20) as a 3.3-kb HindIII-EcoRI partial di-
gest fragment in which the HindIII overhang was filled in by Kle-
now. This was then subcloned into an EcoRI-Xba digest of the
Bluescript plasmid (pBS) in which the Xba overhang was also
blunt-ended, thus regenerating the Xba site. The resulting rTg
promoter was excised using Xba partial digest with ClaI complete
digest. A mHEL construct containing HEL fused to the H-2 K
 
b
 
transmembrane region has been previously described (9). Partial
Xba and complete ClaI digestion of this construct allowed the in-
sertion of the rTg promoter upstream of the mHEL gene. For
oocyte microinjection, the TLK construct was excised with ClaI
and KpnI, purified, and microinjected into C57BL/6 eggs as de-
scribed (6). Two transgenic founders (TLK-1, TLK-2) were ob-
tained and maintained on the B6 background.
 
Animals Used.
 
ML-5 mice expressing soluble HEL (sHEL) at
10–20 ng/ml in the circulation have been previously described
(6). TLK-1, TLK-2, and ML-5 HEL-transgenic mice were screened
by PCR using specific primers for HEL. MD4 Ig transgenic mice
expressing anti-HEL IgM and IgD receptor of the a allotype on
 
.
 
95% of B cells have been previously described (6). Transgene-
positive animals were screened by PCR using specific primers for
the transgenic receptor. Primer sequences and reaction conditions
are available by request.
All animals were maintained on the C57BL/6J (B6) genetic
background and were used between 6 and 20 wk of age. To ob-
tain B6 mice expressing the Ly5
 
a
 
 allele, B6-Ly5
 
a
 
 congenic mice
were bred to B6 (Ly5
 
b
 
) to generate Ly5
 
a/b
 
 heterozygous animals.
 
RT/PCR Analysis.
 
Approximately 50–100-mm
 
3
 
 sections from
various mouse tissues were removed and immediately minced in
4 M guanidine thiocyanate solution (Fluka, Switzerland) contain-
ing 0.1 M 2-mercaptoethanol using a 5-ml glass and teflon tissue
grinder (PGC Scientific, Gaithersburg, MD). Total RNA was ob-
tained using standard procedures. cDNA was prepared from 500
ng total RNA using oligo-dT primer, and PCR was performed
from 1/10 of the cDNA reaction with both actin and HEL prim-
ers in the same reaction mixture.
 
Immunohistochemistry on Frozen Tissue Sections.
 
Thyroid was re-
moved  from CO
 
2
 
 euthanized animals and placed into plastic con-
tainers (Cryomold; Miles, Elkhart, IN), immediately covered in
O.C.T. (Miles), slowly frozen by floating on liquid nitrogen, and
 
stored at 
 
2
 
80
 
8
 
C until cut. 6–10-
 
m
 
m sections were cut on a mi-
crotome at 
 
2
 
20
 
8
 
C and collected onto PTFE-coated slides (Hendley-
Essex, Essex, England). Sections were dried overnight, fixed for
10 min in acetone (at 4
 
8
 
C), and stained in a humid chamber at
room temperature with biotinylated primary antibody (HyHEL-
9-biotin) as described (21). Avidin-alkaline phosphatase second
stage (Sigma Chem. Co., St. Louis, MO) and Fast Red/Naphthol
AS-MX substrate (Sigma) were used to visualize specific staining
as described (21). Sections were counterstained in hematoxylin
and mounted in Crystal/Mount (Biomeda Corporation, Foster
City, CA).
 
Immunization.
 
HEL and chicken gamma globulin (cGG)
were obtained from Sigma. HEL-cGG protein conjugate was the
kind gift of Dr. Kevan Shokat (Howard Hughes Medical Insti-
tute, Stanford University, Stanford, CA). Animals were injected
i.p. with either 100 
 
m
 
g of HEL or 25 
 
m
 
g HEL-cGG emulsified in
200 
 
m
 
l PBS containing RIBI adjuvant (Ribi ImmunoChem Re-
search, Hamilton, MT) as described by the manufacturer. Ani-
mals were either killed on day 14 or 28 after immunization, or
boosted on day 28 with the same amount of HEL or HEL-cGG
in RIBI. Boosted animals were killed and analyzed 7 d later.
 
Anti-HEL Enzyme-Linked Immunosorbent Assay.
 
HEL (Sigma)
was purified on an ion exchange column, dissolved in carbonate
buffer, pH 9.2, and used to coat 96-well flat-bottom plates (Flow
Laboratories, Inc., Mclean, VA). The plates were blocked for 3 h
at 37
 
8
 
C with 10 mg/ml BSA (Pentex, Kankakee, IL). Serum and
standards diluted in 1 mg/ml BSA in PBS, pH 7.5, were then ap-
plied to duplicate wells for 2 h at 37
 
8
 
C. Bound anti-HEL IgG was
developed with goat anti-mouse IgG (Fc specific) conjugated to
alkaline phosphatase (catalog no. A-2429; Sigma), and bound
anti-HEL IgM
 
a
 
 was developed with RS3.1-biotin followed by
streptavidin-alkaline phosphatase (Sigma). Disodium 
 
p
 
-nitrophe-
nyl phosphate (NPP) substrate (Sigma) was then applied and
plates read in a Molecular Devices (Menlo Park, CA) Emax plate
reader at 405 nm. The concentrations of anti-HEL IgM
 
a
 
 were
determined relative to a standard curve of anti-HEL IgM
 
a
 
 from a
transfectoma. Anti-HEL IgG values were calculated in units by
reference to a standard curve of HyHEL-8 anti-HEL IgG
 
1
 
 mAb.
 
Flow Cytometry.
 
Spleen, lymph node, and thymus cells were
isolated by passing through a metal sieve, washed in media con-
taining 2% FCS/RPMI 1640, and counted with a hemocytome-
ter as described (6, 9). Thyrocytes were prepared by mincing two
thyroid lobes with a scalpel blade in serum-free HBSS, washed
once in serum-free HBSS in a 15-ml Falcon tube, and 150 
 
m
 
l of
20 mg/ml collagenase (Boehringer Mannheim, Mannheim, Ger-
many) was added to the pellet. The thyroid lobes were incubated
for 10 min at 37
 
8
 
C with intermittent tapping, washed twice with
2% FCS/RPMI 1640 media, and resuspended in 200 
 
m
 
l media.
100 
 
m
 
l was used for FACS
 
Ò
 
 staining. Cells were analyzed by flow
cytometry on a FACSCAN
 
Ò
 
 (Becton-Dickinson, Mountain View,
CA) with FACS
 
Ò
 
 Desk software (Beckman Center Shared FACS
Facility). The following antigens and antibodies were used: B220,
RA3-6B2-PE (Caltag, South San Francisco, CA) and RA3-6B2-
Fluorescein (FITC; Caltag); Ly5
 
a
 
, AS20-FITC and AS20-biotin;
IgM
 
a
 
, RS3.1-PE and RS3.1-FITC; IgD
 
a
 
, AMS9.1-FITC; HEL-
binding, HEL (Sigma) and HyHEL-9-biotin, or HyHEL9 conju-
gated to cychrome. Biotinylated reagents were detected with
streptavidin-Cychrome (Pharmingen, San Diego, CA). All anti-
body stains were performed on 5 
 
3
 
 10
 
5
 
 cells using standard pro-
cedures as described (6).
 
Adoptive Transfer.
 
Unfractionated spleen cells from Ly5
 
b
 
1
 
 Ig
transgenic mice were isolated as above and analyzed by flow cy-
tometry to determine frequency of HEL-binding transgenic B 
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cells. Spleen cells containing 10
 
7
 
 HEL-binding transgenic B cells
were mixed with 10
 
7
 
 spleen cells from Ly5
 
a/b
 
 nontransgenic mice
and injected into recipients via the lateral tail vein. Recipient an-
imals were sacrificed 5 or 10 d after transfer and analyzed as above
by flow cytometry.
 
Thyroid Blood Flow Calculations.
 
Calculations for blood flow
through mouse thyroid were based on available values from hu-
man (17, 22, 23). As measured fractional cardiac output to various
tissues in the mouse (skin, kidney, heart, muscle) are within 50%
of those measured in human (23), and since fraction of body
weight represented by the thyroid is also similar (0.03% versus
0.02%), we assume that fractional cardiac output to thyroid in the
mouse will also be similar to that in human. Given a fractional
cardiac output value of either 1 or 2.8% to the thyroid, we can
calculate the number of circuits (
 
n
 
) between systemic and pulmo-
nary circulations required before 50 or 99.9% of circulating lym-
phocytes have traveled through the thyroid gland. Assuming
mouse blood volume is 
 
z
 
2.3 ml and C.O. is 16 ml (23), n will be
given in units of 
 
z
 
9-s intervals: if x 
 
5
 
 % C.O. to thyroid, then
(1 
 
2
 
 x) 
 
5
 
 % BV that has not seen thyroid antigen after 15 s.
Solve n (in quantities of 15 s) for:
 
Results and Discussion
 
Transgenic mice expressing membrane-bound HEL on
the thyroid epithelium were produced by microinjecting
C57BL/6 eggs with a gene construct containing 3.3 kb of
the rat thyroglobulin promoter (24) linked to the mem-
brane HEL gene (Fig. 1 
 
a
 
). Two transgenic lines, TLK-1
and TLK-2, were established, and mice from either line
exhibited normal size, body weight, and fecundity, indicat-
ing that the transgene did not induce overt thyroid insuffi-
ciency. RT-PCR analysis of various tissues revealed that
most or all mHEL RNA expression is restricted to the thy-
1 ( x )
n
0.5 time for 50% cells through gland () = –
or
1 ( x )
n
0.001 time for 99.9% cells through gland () = –
n
log 0.5 ()
log 1 x – ()
----------------------      or      
log 0.001 ()
log 1 x – ()
----------------------- =
Figure 1. C57BL/6 trans-
genic mice expressing mHEL on
thyroid epithelium. (A) Structure
of microinjected hybrid gene
containing 3.3 kb of the rTg pro-
moter attached to the HEL gene,
to which the H-2Kb transmem-
brane domain (Kb TM) has been
added. X, XbaI; H, HindIII; C,
ClaI;  K, KpnI. (B) RT/PCR
analysis of various tissues from
nontransgenic, TLK-2 trans-
genic, and KLK-4 transgenic
mice. KLK-4 mice express
mHEL in all tissues under the Kb
MHC class I promoter. Oligo-
dT–primed cDNA was made
from the following tissue RNA:
1, spleen; 2, liver; 3, thymus; 4,
heart; 5, kidney; 6, thyroid. PCR
was performed using cDNA tem-
plate and specific primers for
both HEL and actin in one reac-
tion. (C) Immunohistochemical
staining for HEL in TLK-1 and
TLK-2 thyroids. 10-mm frozen sections of one thyroid lobe from each line was stained using a biotinylated anti-lysozyme mAb, streptavidin-alkaline phos-
phatase secondary stage, and Fast red substrate (red). Hematoxylin (blue) was used for counter-staining. (D) Flow cytometric analysis of thyrocytes from
nontransgenic (thin line) or TLK-2 transgenic (thick line) mice stained for cell surface HEL. The percent positive cells is indicated. 
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roid (Fig. 1 
 
b
 
). Immunohistochemical analysis of thyroid
gland from both lines revealed abundant HEL expression
on many follicular epithelial cells (Fig. 1 
 
c
 
). Western blot-
ting showed that the membrane-bound form of HEL was
made in large quantities in the TLK-2 thyroid (25), and
FACS
 
Ò
 
 staining of thyrocytes confirmed surface expression
of HEL (Fig. 1 
 
d
 
). There was no evidence of inflammation
in any of the mice, and follicular architecture was normal
except in a fraction of older mice from the TLK-2 line
(data not shown). The latter animals displayed moderately
enlarged thyroids, with follicles that appeared hyperplastic
and consisted of cuboidal epithelium, although there was
no evidence for inflammation. Because the TLK-2 line ex-
presses higher levels of HEL than TLK-1, the cytopathol-
ogy present in a fraction of older TLK-2 animals may be a
direct effect of transgene expression, as described previ-
ously (26–28), but appears not to affect acquisition of im-
mune tolerance (see below).
To determine whether or not thyroid mHEL expression
resulted in tolerance to HEL, TLK-1 or TLK-2 transgenic
mice and nontransgenic littermates were immunized with
HEL. Nontransgenic mice mounted normal primary and
secondary IgG responses to HEL, whereas very little anti-
body was produced in transgenic mice (Fig. 2 
 
a
 
). Thus,
thyroid mHEL animals actively acquired tolerance to HEL
either at the B or T cell level, or both. To focus on the B
cell repertoire, any T cell tolerance to HEL that may have
been acquired was bypassed by immunizing with HEL an-
tigen covalently linked to a foreign carrier, chicken gamma
globulin (HEL-cGG). After HEL-cGG immunization, HEL-
specific IgG was produced in equal titers in nontransgenic
and transgenic mice from both TLK lines (Fig. 2 
 
b
 
). This
result therefore indicated either that preimmune B cells
were not censored to HEL or that provision of potent T
cell help to the cGG carrier was able to override B cell
elimination or inactivation.
The status of circulating HEL-specific B cells in the pre-
immune repertoire was directly examined by crossing TLK-1
and TLK-2 thyroid mHEL transgenic mice with Ig trans-
genic mice that express high-affinity HEL-specific IgM and
IgD on 90% of circulating B cells (6). When Ig 
 
3
 
 TLK
double-transgenic mice were compared with littermates
carrying only the Ig transgene, no differences in B cell phe-
notype (Fig. 3 
 
a
 
) or number could be detected in spleen
(Fig. 3, 
 
a
 
 and 
 
b
 
), lymph node, or bone marrow (not
shown). This contrasted with the change in B cell pheno-
type in mice expressing circulating sHEL antigen (Fig. 3 a)
(6) or the deletion of HEL-binding B cells in mice express-
ing mHEL in a systemic distribution (9). In addition, serum
levels of transgenic anti-HEL IgMa were not reduced in Ig-
transgenic animals expressing thyroid mHEL compared
with Ig transgenic mice lacking HEL (Fig. 3 c), unlike the
inhibition of anti-HEL autoantibody secretion in mice ex-
pressing HEL systemically (6, 9).
The large number of HEL-specific B cells that are con-
stantly produced in Ig-transgenic mice may in principle
have obscured deletion of small, physiological frequencies
of autoreactive B cells by encounter of HEL on the thy-
roid. To test this possibility, small numbers of naive, ma-
ture HEL-specific Ig-transgenic cells were introduced into
the bloodstream of unirradiated nontransgenic or TLK
transgenic mice and allowed to recirculate for 5 or 10 d. To
provide an internal standard for the transfer and ensure de-
tection of subtle losses of HEL-specific B cells, Ly5a-
marked nontransgenic spleen cells were coinjected with the
Ly5b Ig-transgenic cells. The behavior of these Ly5a non-
transgenic B cells should not be affected by the presence or
absence of HEL antigen. Despite the presence of only trace
numbers of circulating HEL-reactive B cells, their number
and ratio to nontransgenic standard B cells was not signifi-
cantly different in TLK recipients with high expression of
mHEL in the thyroid gland compared to non-transgenic
recipients lacking HEL autoantigen (Fig 4 a).
The maintenance of tolerance to organ-specific self anti-
Figure 2. Anti-lysozyme IgG response in high-responder H-2k/b F 1
nontransgenic and TLK transgenic mice. (A) Mice were immunized i.p.
with 100 mg HEL in RIBI adjuvant. (B) Mice were immunized i.p. with
25 mg HEL-cGG in RIBI adjuvant. In both cases, day 35 data represent
secondary responses 7 d after boosting with HEL/RIBI or HEL-cGG/
RIBI, respectively. HEL binding IgG was measured by ELISA in serum
of individual mice (dots), and geometric means are shown in bars.2009 Akkaraju et al.
rials and Methods for calculations). On the other hand, the
continuous endothelium lining the capillary beds surround-
ing thyroid follicles is likely to create a physical barrier
against preimmune B cells contacting thyroid mHEL. In
the absence of inflammation, the thyroid capillary endothe-
lium lacks the addressins to allow trafficking of preimmune
B cells into the organ parenchyma (29). By contrast, elimi-
nation of circulating autoreactive B cells to liver-specific
H-2Kb membrane autoantigen (15) may reflect the fact that
hepatocytes do not have such a barrier between their
plasma membrane and circulating cells (30).
The physical barrier between blood and thyroid paren-
chyma created by endothelium and basement membrane
may also prevent initiation of inflammation by circulating
anti-thyroid autoantibody. In this regard, it is noteworthy
that production of serum anti-HEL autoantibody (Figs. 2
and 3) did not trigger signs of autoimmune thyroid pathol-
ogy in (TLK 3 Ig) double-transgenic mice or in immu-
nized TLK mice (data not shown). Since the Ig transgenic
mice use the IgM constant region for secreted antibody,
pentameric IgM autoantibody would be limited to the in-
travascular fluid (31), except after tissue inflammation had
been initiated. The IgG antibodies induced with HEL-
cGG immunization (Fig. 2 b), on the other hand, may gain
access to the basal plasma membrane of noninflamed thy-
roid epithelium to a limited extent by diffusion through
large pores in the capillary network or via transcytosis
Figure 3. Lack of B cell toler-
ance in TLK transgenic mice
crossed to anti-lysozyme Ig trans-
genic mice. (A) Two-color
FACSÒ analysis of spleen cells from
nontransgenic, Ig transgenic, and
Ig  3 TLK double-transgenic
mice. HEL-binding B cells were
identified by staining cells with
an excess of unlabeled HEL be-
fore secondary staining with a
complementary biotinylated anti-
HEL monoclonal antibody. RS-
3.1 (anti-IgMa) co-staining reveals
that the HEL-binding cells are all
expressing transgenic (a-allotype),
rather than endogenous (b-allotype),
receptor. For comparison, spleen
cells from Ig 3 ML-5 double-
transgenic mice expressing solu-
ble HEL systemically are shown,
illustrating the phenotypic changes
occurring in anergic self-reac-
tive B cells (6). (B) Number of
anti-HEL splenic B cells in Ig
transgenic and Ig 3 TLK dou-
ble-transgenic mice, measured
as in A. (C) Serum levels of anti-
HEL IgMa (transgenic) antibody.
No reduction in spontaneous se-
cretion of transgenic anti-lysozyme
antibody is seen in Ig 3 TLK
double-transgenic mice compared
to Ig-transgenic littermates.
gens is vital for the avoidance of autoimmune diseases such
as Type I Diabetes, Hashimoto’s thyroiditis, Graves’ Dis-
ease, and Myasthenia Gravis. In this report, we demonstrate
that expression of HEL specifically on the thyroid epithe-
lium resulted in actively acquired tolerance that could not
be broken by immunization with HEL in adjuvant. Hu-
moral tolerance to thyroid HEL did not result, however,
from the elimination or functional inactivation of high af-
finity autoreactive B cells from the circulating preimmune
repertoire, in contrast to tolerance to systemic HEL (6).
Thus, humoral tolerance to thyroid mHEL could easily be
broken by immunization with a conjugate that linked self-
HEL epitopes to a foreign carrier (Fig. 2 b). Crosses or cell
transfer with anti-HEL Ig-transgenic mice clearly estab-
lished that thyroid mHEL did not eliminate or inactivate
HEL-reactive B cells at appreciable efficiency (Figs. 3 and 4).
Two factors may in principle explain the failure of ac-
tively acquired B cell tolerance to thyroid-specific surface
HEL antigen: (a) very few B cells may pass through the
thyroid circulatory bed; or (b) circulating B cells may be
kept separate from HEL on thyroid epithelium by the base-
ment membrane and vascular endothelium. The former is
unlikely based on the pattern of thyroid blood flow and
proportion of cardiac output received in humans (17; Table
1), which predicts that all circulating B cells should traffic
through the thyroid many times in the 5- or 10-d period
studied in the experiments of Fig. 4 (Table 1 and see Mate-2010 B Cell Tolerance to Thyroid Surface Antigen
across the endothelium (32, 33). Nonetheless, bound IgG
may not be sufficient to induce complement and recruit in-
flammatory cells on its own due to low concentrations of
complement and inflammatory cells in healthy tissue and to
the thyroid’s intrinsic ability to inhibit complement activa-
tion via CD46, CD55, and CD59 (34, 35). Indeed, differ-
ent EAT models have not shown a correlation of inflam-
mation to anti-thyroglobulin, anti-TPO, or anti-TSH receptor
antibody (18, 36–38).
Failure of active B cell tolerance may occur for tissue-
specific antigens in many different parenchymal organ sys-
tems with comparable vascular barriers to the thyroid. In-
deed, preimmune B cells are also not censored in transgenic
mice expressing mHEL in pancreatic islet beta cells (ILK-3
transgenic line, data not shown). These results imply that
secretion of pathogenic autoantibodies in autoimmune dis-
eases such as Graves’ disease, Myasthenia Gravis, Bullous
Pemphigoid, and Goodpasture’s Disease is not controlled at
the level of preimmune B cells. These autoantibodies may
arise when T cell tolerance is bypassed by immunological
challenges with cross-reactive foreign antigens or with self
antigen that became coupled to a foreign carrier (Fig. 2, a
and b), or when T cell tolerance breaks down. It will be
important in future work to determine the extent to which
thyroid-specific antigens trigger active regulation of self-
reactive T cells or censoring of B cells at later stages of the
immune response, for example in local germinal centers or
when the thyroid becomes inflamed and B cells are at-
tracted into the organ.
Figure 4. Small numbers of circulating HEL-specific B cells are not
eliminated in thyroid mHEL transgenic mice. Non-transgenic, TLK-1, or
TLK-2 C57BL/6 mice were injected i.v. with a mixture of C57BL/6
(Ly5b) Ig-transgenic splenic B cells and C57BL/6 Ly5a/b non-transgenic
spleen cells. Cells were left in the primary recipients either 5 or 10 d. (A)
Frequency of transgenic anti-HEL B cells per spleen remaining in each
recipient (dots) and geometric mean (bars) after 10 d. To detect subtle
changes, the cell frequencies per recipient are corrected for the injected
dose of cells by dividing by the ratio of percentage of Ly5a1, nontrans-
genic B cells remaining in each recipient and average percentage of Ly5a1,
nontransgenic B cells in all recipients. (B) FACSÒ analysis of representa-
tive spleens from 10-d parking recipients. Transferred Ig transgenic B cells
are double-positive for IgDa and HEL binding; percentage of cells dou-
ble-positive for IgDa staining and HEL binding is given in the upper right
corner. All transgenic cells express a high level of IgDa, but expression of
IgMa on these IgDa-positive, HEL-binding cells is reduced 2–3-fold by
exposure to the TLK-2 environment.
Table 1. Summary of Thyroid Circulatory Parameters
Human Mouse
Cardiac output (C.O.) 5 liter/min 16.0 ml/min
Thyroid weight 20 g 4.5 mg
Body weight 70 kg 25 g
Thyroid blood flow 5 ml/g/min ???
% body weight (thyroid) 0.03% 0.02%
% C.O. to thyroid 2.8% ???
Table 2. Calculation Times for 50 or 99.9% Circulating 
Lymphocytes to Pass through Thyroid Gland
% C.O. to
thyroid (x) (1 2 x) time 50% time 99.9%
min
2.8% 97.2% 3.66 36.49
1.0% 99.0% 10.34 103.102011 Akkaraju et al.
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